Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
Ivo ABRAHAM / POSITION TITLE
Professor of Pharmacy and Medicine; Director, Center for Health Outcomes and Pharmacoeconomic Research; Arizona Cancer Center
eRA COMMONS USER NAME (credential, e.g., agency login)
iabraham
EDUCATION/TRAINING
INSTITUTION AND LOCATION / DEGREE
(if applicable) / MM/YY / FIELD OF STUDY
Leuven University College (Leuven, Belgium) / BS / 1979 / Psychiatric nursing
University of Michigan (Ann Arbor, MI) / MS / 1982 / Psychiatric-mental
health nursing
University of Michigan (Ann Arbor, MI) / PhD / 1984 / Clinical research
Universität Basel (Basel, Switzerland)
Vlerick Business School (Leuven, Belgium) / 2003
2011 / Pharmaceutical medicine
Entrepreneurship and innovation in life sciences
A. Personal Statement
As a clinically trained methodologist in clinical research and specifically clinical outcomes and comparative effectiveness research, my work over the past 30+ years has focused on interventions ranging across the full spectrum from singular molecules over aggregate interventions to models and systems of care; considering clinical, patient-centered, and economic outcomes from the patient to the population levels; and integrating complex designs and analytics from the health, social, and behavioral sciences. My work has integrated three continua: molecules to models of care; patients to populations; and empirics to evidence. I have been funded continuously for the past 30 years by US (NIH, NIMH, NIA, HRSA) and foreign governmental funding agencies, foundations, and corporations; and I have served as appointed or ad hoc reviewer for US, European, and Japanese funding agencies.
B. Positions and Honors
Positions and Employment
1984-1988 Case Western Reserve University (Cleveland, OH). Assistant Professor (1984-1986), Associate
Professor (1986-1988), and Director of Research (1985-1987), Frances Payne Bolton School of
Nursing.
1989- University of Virginia (Charlottesville, VA). Associate Professor (1989–1992) Professor (1992-
1997), and Clinical Professor (1998-present), School of Nursing; Associate Professor, Department
of Psychiatric Medicine, School of Medicine (1989-1997). Founding Director, Center on Aging and Health (1991-1996), Founding Co-Director NIMH P50 Southeastern Rural Mental Health Research Center (1992-1994).
1992-1999 Katholieke Universiteit Leuven (Leuven, Belgium). Professor, Center for Health Services and
Nursing Research, School of Public Health, Faculty of Medicine (part-time).
1998-2003 The Epsilon Group (Charlottesville, VA, & Leuven, Belgium). Founding President and CEO.
2003- Matrix45 (Tucson, AZ). Founding Principal and Chief Scientist.
2004-2009 University of Arizona (Tucson, AZ). Adjunct Clinical Professor (2004-2007) and Professor (2007-
2009) (part-time), College of Nursing.
2008- University of Arizona (Tucson, AZ). Professor, Department of Pharmacy Practice and Science, College of Pharmacy; Department of Family and Community Medicine, College of Medicine; Director, Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy; Member, Arizona Cancer Center, Arizona Center on Aging, and Center for Biomedical Informatics and Biostatistics.
Visiting Appointments: Maastricht University (The Netherlands), University of Florida (Gainesville, FL), University of Groningen (The Netherlands), University of Pennsylvania (Philadelphia, PA), Chang Gung University (Kwei-Shan, Tao-Yuan, Taiwan), Hyogo University (Kobe, Japan).
Federal and International Scientific Review Appointments (selected from 20 since 1985)
1987-1991 Charter Member, Nursing Research Study Section, NIH
1992-1997 Mental Disorders of the Aging Review Committee, NIMH
2007- European Union Expert Panel on Health Care, Directorate General for Research
2008- Member, Scientific Merit Review Board, Health Services Research and Development, U.S. Department of Veterans Administration.
2008- Expert Panel, Innovative Medicines Initiative Joint Undertaking, European Union and European Federation of Pharmaceutical Industries and Associations.
Honors (selected from 26 since 1981)
1989 American Journal of Nursing Book of the Year Award (Research)
1993 Gallmann Distinguished Lecture, University of Texas at Austin
2003 American Journal of Nursing Book of the Year Award (Gerontology)
2007 Anna Reynvaan Scientific Price (Amsterdam, The Netherlands)
2007-2008 Invitational Research Fellowship, Japan Society for the Promotion of Science
2008 Jubiläum Festrede, Institut für Pflegewissenschaft, Universität Basel (Switzerland)
C. Selected Peer-Reviewed Publications Relevant to Application (15 selected from 416 publications since 1981; lead, senior or corresponding author only; current/past trainees/mentees/students underlined)
Villa L, Sun D, Denhaerynck K, Vancayzeele S, Brié H, Hermans C, Aerts A, Levengood M, MacDonald K, Abraham I. Predicting blood pressure outcomes using single-item physician-administered measures: a retrospective pooled analysis of observational studies in Belgium. British Journal of General Practice 2015;65:15-16 (Abridged text in print. Full text: DOI: 10.3399/bjgp15X683101).
Devogelaer JP, Geusens P, Daci E, Gielen E, Denhaerynck K, MacDonald K, Hermans C, Vancayzeele S, Abraham I, Boonen S. Remission over three years in patients with Paget’s disease of bone treated with a single intravenous infusion of 5mg zoledronic acid. Calcified Tissue International 2014;94:311-318.
Van Meerbeeck J, Galdermans D, Bustin F, De Vos L, Lechat I, Abraham I. Survival outcomes in patients with advanced non-small-cell lung cancer treated with erlotinib: expanded access program data from Belgium (the TRUST study). European Journal of Cancer Care 2014;23:370-379.
Delforge M, (…), Harrington A, MacDonald K, Abraham I, Ravoet C. Adequate iron chelation therapy for at least six months improves mortality in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leukemia Research 2014;38:557-563.
Abraham I, MacDonald K, Tharmarajah S, Bokemeyer C, Ludwig H, Soubeyran P, Battistel V, Aapro M. Modeling of treatment response to erythropoiesis-stimulating agents in older (age 70 years) and younger (age < 70 years) cancer patients with anemia: findings from the Anemia Cancer Treatment study. Journal of Geriatric Oncology 2013;4:196-201.
Abraham I, MacDonald K, Song MK, Ciesielski G, Pacheco C, Lee C, Cholette M, Kinsey K, Speaks P, Hermans C, Brié H, Reel S, Van der Niepen P, Yee B, Vancayzeele S. Patient- and physician-level determinants of blood pressure response to treatment in normal and overweight patients (The PREVIEW Study). Nutrition, Metabolism & Cardiovascular Diseases 2013;23:314-322.
Abraham I, Van Camp Y, Villa L, Denhaerynck K, Sun D, Vancayzeele S, Aerts A, Brié H, Hermans C, MacDonald K. Hierarchical modeling of patient and physician determinants of blood pressure outcomes in adherent versus non-adherent hypertensive patients: pooled analysis of six studies with 14,646 evaluable patients. Journal of Clinical Hypertension 2013;15:663-673.
Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, MacDonald K, Abraham I. Real-world variability in ranibizumab treatment and associated clinical and quality of life outcomes in patients with neovascular age-related macular degeneration: the HELIOS study. Clinical Ophthalmology 2013;7:1849-1858.
Abraham I, Sun D. The cost of blood transfusion in Western Europe as estimated from six studies. Transfusion 2012; 52:1983-1988.
Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet, C. (2011). Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Annals of Hematology 2011;90:655-666.
MacDonald K, Lee CS, Chen HC, Ko M, Fidel G, Brié H, Hermans C, Vancayzeele S, Reel S, Van der Niepen P, Abraham I. Gender-specific, multi-level determinants of outcomes of antihypertensive treatment: a sub-analysis of the Belgian PREVIEW Study. Journal of Human Hypertension 2011;25:372-382.
Abraham I. Intravenous bisphosphonate treatment and osteonecrosis of the jaw in patients with cancer: wide CIs, Yule-Simpson and King Kong effects, and no therapeutic outcomes. Journal of Clinical Oncology 2010;28:e143-e144.
Aapro M, Ludwig H, Bokemeyer C, MacDonald K, Soubeyran P, Turner M, Albrecht T, Abraham I. Modeling of outcomes and response rates to treatment with erythropoiesis stimulating agents in cancer patients with anemia: findings from the Anemia Cancer Treatment (A.C.T.) study. Annals of Oncology 2009;20:1714-1721.
Ludwig H, Aapro M, Bokemeyer C, MacDonald K, Soubeyran P, Turner M, Albrecht T, Abraham I. Treatment patterns, outcomes, and response rates in the management of cancer-related anemia in Europe: findings from the Anemia Cancer Treatment (A.C.T.) study. European Journal of Cancer 2009;45:1603-1615.
Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-5411.
D. Selected Research Support Relevant to Application (selected from 215+ grants/contracts since 1984)
Ongoing Research Support of Relevance to this Application (selected)
NHLBI J. Garcia, PI 2014-2017
R25T PRIDE Advanced health disparities training program in heart, lung, blood, and sleep conditions
Faculty
NCI D. Alberts, PI 2012-2015
R25T CURE postdoctoral fellowship for T. Nuño.
Mentor
USDHHS S. Reel, PI 2013-2016
Health 360
USDHHS P. Lebensohn, PI 2014-2017
Center for Integrative Medicine Primary Care
Saudi Arabian Cultural Mission PI 2012-2016
Clinical Research in Human Therapeutics
Saudi Arabian Cultural Mission PI 2012-2016
Clinical Outcomes and Comparative Effectiveness Research
Past Federal Funding
Co-PI, R01, “Dyadic vulnerability/risk profiling for elder neglect”. Fulmer, PI. NIA 2000-2003
Co-PI, P50, “Southeastern rural mental health research center.” Fox, PI. NIMH 1992-1997
Co-I, T36, “Psychiatric and family nurse practitioner program.” Hauenstein, PI. NIMH 1992-1995
Co-PI T36 “Multidisciplinary training in schizophrenia and psychogeriatrics.” Fox, PI. NIMH 1989-1992
Co-PI P50, “Institute on community integration of the long-term mentally ill.” Fox, PI. NIMH 1998-1991
PI R01, “Nursing treatments for depressed aged in long-term care.” NINR 1987-1990
CoPI R01, “Aged cohort comparison in acute psychiatric facility.” Wykle, PI. NIMH 1987-1989
PI, “Biomedical research support grant.” NIH 1985-1988
Co-I, P50, “Teaching nursing home project”. Ford, PI. NIA 1984-1988
Co-PI and project PI, “Nursing research emphasis grant”. Fitzpatrick PI (1984-1988).
Co-I, P50 “Northeast Ohio multipurpose arthritis center.” Moskowitz PI. NIH (1984-1988).
Several (co-)sponsorships of NRSA and K-awards
Past Foundation Funding (selected)
Robert Wood Johnson Foundation
Pew Charitable Trust
W.K. Kellogg Foundation
John A. Hartford Foundation
The Cleveland Foundation
American Society of Health-System Pharmacists Foundation
Japan Society for the Promotion of Science
PHS 398/2590 (Rev. 06/09) Page Biographical Sketch Format Page